Halogen Or Nitrogen Containing (e.g., 20-cyano-pregnanes, 21-cyano Pregnenes, Etc.) Patents (Class 552/554)
-
Patent number: 11072630Abstract: The present invention relates to fluorinated and alkylated bile acids.Type: GrantFiled: March 10, 2016Date of Patent: July 27, 2021Assignee: Metselex, inc.Inventors: Michael Finch, Cyrus B. Munshi, Cecilia M. P. Rodrigues, Susana Dias Lucas de Oliveira
-
Publication number: 20150140063Abstract: A hydrophobic cationic steroidal anti-microbial (ceragenin) compound forms an amphiphilic compound having a hydrophobic sterol face and a hydrophilic cationic face. The hydrophobic CSA also includes a hydrophobic substituent that gives the ceragenin compound a C Log P value of at least 6.0, 6.25, 6.5, 7.5, 8.5, or 10.Type: ApplicationFiled: January 22, 2015Publication date: May 21, 2015Applicant: BRIGHAM YOUNG UNIVERSITYInventor: Paul B. Savage
-
Publication number: 20150132228Abstract: The present invention relates to the synthesis and use of a novel trifluorinated bile acid analogue, that being, CA-sar-TFMA which is useful as an imaging probe, diagnostic agent or contrast agent and is resistant to bacterial deconjugation, wherein the trifluorinated bile acid analogue can be used as a 19F MRI tracer exhibiting an increased half-life due to its resistance to choloylglycine hydrolase.Type: ApplicationFiled: November 7, 2014Publication date: May 14, 2015Inventors: JAMES E. POLLI, JEAN-PIERRE RAUFMAN, DIANA VIVIAN
-
Publication number: 20150017093Abstract: The present invention relates in one aspect to radiolabeled compounds comprising the structure of Formula 1. The radiolabeled compounds are preferably bile acids or bile acid derivatives. Further aspects of the invention relates to use of the compounds comprising the structure of Formula 1 in imaging methods such as for example PET, imaging method using a compound comprising the structure of Formula 1, administering said compound to an individual and making a radiographic image of a region of interest from said individual.Type: ApplicationFiled: January 29, 2013Publication date: January 15, 2015Applicants: Aarhus Universitet, Region MidtjyllandInventors: Susanne Keiding, Peter Ott, Michael Sorensen, Kim Frisch, Alan Hofmann
-
Publication number: 20150005269Abstract: A method of reducing heart failure or preventing sudden cardiac death in a subject in need thereof is carried out by administering a composition comprising a compound that increases cellular level of Sarco/endoplasmic reticulum Ca2+-ATPase 2a (SERCA2a). The invention represents a significant breakthrough in the treatment or prevention of chronic heart failure. The invention is based upon the discovery that a Mifepristone molecule increases the cellular level of SERCA2a protein.Type: ApplicationFiled: January 3, 2013Publication date: January 1, 2015Inventors: Gideon Koren, Zhe Zheng
-
Publication number: 20140363780Abstract: Described herein are aqueous and substantially non-aqueous oral compositions comprising a cationic steroidal compound and methods of making and using the same.Type: ApplicationFiled: July 23, 2014Publication date: December 11, 2014Applicant: BRIGHAM YOUNG UNIVERSITYInventors: Joe Vazquez, Dandan Chen, Harsh M. Trivedi, Ammanuel Mehreteab, Laurence Du-Thumm, Gregory Szewczyk, Zhigang Hao
-
Publication number: 20140343023Abstract: The present invention relates to compounds of formula I, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention, suppression or amelioration of a disease mediated by the ROR gamma receptor in a subject in need thereof, in particular diabetes and diabetes-related disorders, specifically type II diabetes, methods of their production, as well as methods of treatment or prevention of such diseases.Type: ApplicationFiled: September 18, 2012Publication date: November 20, 2014Inventors: Christian Wolfrum, Erick Carriera, Bettina Meissburger
-
Publication number: 20140271819Abstract: Polymorphic forms of onapristone and methods of making and using such polymorphic forms are provided. Crystalline polymorphic forms can be characterized by their X-ray powder diffraction patterns and other properties.Type: ApplicationFiled: March 11, 2014Publication date: September 18, 2014Inventor: STEFAN PRONIUK
-
Publication number: 20140220122Abstract: The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo.Type: ApplicationFiled: April 7, 2014Publication date: August 7, 2014Applicant: BHI Limited PartnershipInventors: Xianqi KONG, Mohamed ATFANI, Benoit BACHAND, Abderrahim BOUZIDE, Stephane CIBLAT, Sophie LEVESQUE, David MIGNEAULT, Isabelle VALADE, Xinfu WU, Daniel DELORME
-
Publication number: 20140206657Abstract: Provided herein are bile acid analogues and derivatives, methods of synthesizing bile acid analogues and derivatives and their use in treating diabetes and liver disease.Type: ApplicationFiled: January 21, 2014Publication date: July 24, 2014Applicant: City of HopeInventors: Donna Yu, Barry Forman, Wendong Huang, Kyle Sousa
-
Publication number: 20140107089Abstract: Disclosed are compounds having the general formula: wherein R1-R4 and X are as defined herein, pharmaceutical compositions including such compounds, and a method of treating a patient involving antagonizing the endogenous progesterone, such as in inducing menses and treating endometriosis, dysmenorrhea, endocrine hormone-dependent tumors, meningiomas, uterine leiomyomas, or uterine fibroids, inhibiting uterine endometrial proliferation, inducing cervical ripening, inducing labor, and in contraception.Type: ApplicationFiled: September 10, 2013Publication date: April 17, 2014Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Hyun K. Kim, Richard P. Blye, Pemmaraju N. Rao, James W. Cessac, Carmie K. Acosta, Anne Marie Simmons
-
Publication number: 20140024631Abstract: The invention relates to compounds of formula (I): wherein R is ethyl, propyl or allyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.Type: ApplicationFiled: February 7, 2013Publication date: January 23, 2014Applicant: INTERCEPT PHARMACEUTICALS, INC.Inventor: INTERCEPT PHARMACEUTICALS, INC.
-
Publication number: 20130316995Abstract: The invention relates to fatty acid statin conjugates and fatty acid FXR agonist conjugates; compositions comprising an effective amount of a fatty acid statin conjugate or a fatty acid FXR agonist conjugate; and methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid statin conjugate or a fatty acid FXR agonist conjugate.Type: ApplicationFiled: May 1, 2013Publication date: November 28, 2013Applicant: Catabasis Pharmaceuticals, Inc.Inventor: Catabasis Pharmaceuticals, Inc.
-
Patent number: 8586770Abstract: The invention relates to methods to manipulate stem cells in vivo and in vitro to treat, e.g., a condition where cell or tissue repair is needed.Type: GrantFiled: February 18, 2011Date of Patent: November 19, 2013Assignee: Harbor Therapeutics, Inc.Inventor: James M. Frincke
-
Publication number: 20130203718Abstract: The present invention relates to a compound of formula (I): for its use as progesterone receptor antagonist, in particular for its use for the prevention and/or the treatment of cancer or uterine pathologies.Type: ApplicationFiled: May 9, 2011Publication date: August 8, 2013Inventors: Marie-Edith Rafestin-Oblin, Mouad Alami, Hugues Loosfelt, Abdallah Hamze, Ali Junaid Khan, Abdellatif Tikad, Marc Lombes, Jean-Daniel Brion
-
Publication number: 20130165658Abstract: This invention is directed to a process for the preparation of high yield alkyl or aryl iodide from its corresponding carboxylic acid using N-iodo amides.Type: ApplicationFiled: June 9, 2011Publication date: June 27, 2013Inventors: Gennady Nisnevich, Mark Gandelman, Kseniya Kulbitski
-
Publication number: 20130029953Abstract: Described herein are compounds which either act as pure antiprogestins or as antiprogestins with partial agonistic activity and methods of treating cancer using such compounds.Type: ApplicationFiled: July 28, 2011Publication date: January 31, 2013Inventors: Klaus Nickisch, Kesavaram Narkunan, Baishakhi Debnath, Bindu Santhamma
-
BILE ACIDS AND BIGUANIDES AS PROTEASE INHIBITORS FOR PRESERVING THE INTEGRITY OF PEPTIDES IN THE GUT
Publication number: 20120035116Abstract: This invention relates to methods of preserving the integrity of peptides in the gut. In particular it concerns the use of certain compounds as inhibitors of gut proteases. Compounds identified as having gut protease inhibitory activity are biguanides, certain bile acids and pharmaceutically acceptable salts of these compounds. This activity makes these compounds useful for co-administration with prophylactic or therapeutic peptides. This invention relates to methods of inhibiting gut proteases and peptide formulations comprising these gut protease inhibitor.Type: ApplicationFiled: October 1, 2009Publication date: February 9, 2012Inventors: Roger R., C. New, Glen Travers -
Publication number: 20110295025Abstract: A process for the preparation of cholyl-L-lysine comprising the steps of: —(a) reacting N-?-CBZ-cholyl-L-lysine with a hydrogen source in the presence of a catalyst in a solvent comprising one or more alkanols; (b) removing the catalyst; (c) optionally diluting the resulting reaction mixture with water and optionally adjusting the pH of the resultant reaction mixture to a pH less than or equal to about 4; (d) removing the bulk of the alkanol whilst ensuring that the alkanol content of the resultant mixture is maintained above about 3% w/w of the remaining mixture; (e) extracting the resultant mixture from step (d) with an organic solvent; (f) adjusting the pH of the aqueous layer to a pH of about 4.5 or greater to precipitate cholyl-L-lysine; (g) isolate the precipitate.Type: ApplicationFiled: February 10, 2010Publication date: December 1, 2011Inventors: Tomos Huw Roberts, Dafydd Thomas
-
Publication number: 20110287436Abstract: Methods of detecting at least one analyte and at least one nucleic acid in a sample are provided. Reagents for carrying out the methods are also provided.Type: ApplicationFiled: July 29, 2011Publication date: November 24, 2011Applicant: Applied Biosystems, LLCInventors: Mark E. Shannon, David W. Ruff
-
Publication number: 20110250538Abstract: New methods are provided for synthesis of photoacid generator compounds (“PAGs”), new photoacid generator compounds and photoresist compositions that comprise such PAG compounds. In a particular aspect, sulfonium-containing (S+) photoacid generators and methods of synthesis of sulfonium photoacid generators are provided.Type: ApplicationFiled: December 10, 2010Publication date: October 13, 2011Applicant: Rohm and Haas Electronic Materials LLCInventors: Mingqi LI, Emad AQAD, Cong LIU, Joseph MATTIA, Cheng-Bai XU, George G. BARCLAY
-
Publication number: 20110237504Abstract: A delivery agent for delivering a biologically active agent to a warm-blooded animal includes a hydrophobic moiety covalently bonded to a hydrophilic moiety. The hydrophobic moiety can include bile acids, sterols, or hydrophobic small molecules. The hydrophilic moiety can include ?-amino acids, dipeptides or tripeptides, or hydrophilic small molecules. An illustrative delivery agent is N?-deoxycholyl-L-lysine-methylester. The delivery agent and the biologically active agent are mixed together to form a complex, which is then administered to the animal. These complexes are particularly useful for oral administration of biologically active agents, but other routes of administration may be used.Type: ApplicationFiled: March 15, 2011Publication date: September 29, 2011Inventors: Youngro Byun, Seulki Lee, Hyuntae Moon
-
Publication number: 20110144281Abstract: The present invention relates to a polymer comprising a cholane core having at least one derivatizable group covalently bonded thereto and a hydrophilic polymer chain covalently bonded to derivatizable group(s) and a process for producing it The present invention also relates to micellar aggregate formed from the polymer of the present.Type: ApplicationFiled: December 5, 2008Publication date: June 16, 2011Applicant: VALORISATION-RECHERCHE, SOCIETE EN COMMANDITEInventors: Xiao-Xia Zhu, Juntao Luo, Guillaume Giguere
-
Patent number: 7858608Abstract: The present invention relates to compounds of formula (I) wherein: R1 is hydrogen or an alkyl group; R2 is hydrogen or a halogen, nitro, alkyloxy, amino or carboxy group; Y is CH2, oxygen or sulfur; n is an integer from 1 to 4, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof for the treatment of FXR-mediated diseases or conditions.Type: GrantFiled: May 4, 2009Date of Patent: December 28, 2010Assignee: Intercept Pharmaceuticals, Inc.Inventors: Roberto Pellicciari, Stefano Fiorucci, Mark Pruzanski
-
Publication number: 20100273759Abstract: Described herein are compounds which exhibit progesterone antagonistic effects and methods of treating cancer using such compounds.Type: ApplicationFiled: March 29, 2010Publication date: October 28, 2010Inventors: Klaus Nickisch, James Cessac, Kesavaram Narkunan, Baishakhi Das
-
Publication number: 20100093687Abstract: A method of treating a disorder related to a high cholesterol concentration, comprising administering to a subject in need thereof a compound of formula (I): Also disclosed are methods, kits, combinations, and compositions for treating a disorder in a subject where an activator of liver X alpha is indicated, such as in, for example, treating a high cholesterol disease.Type: ApplicationFiled: December 14, 2009Publication date: April 15, 2010Applicant: University of ChicagoInventors: Ching Song, Shutsung Liao, Qing Dai
-
Patent number: 7678782Abstract: Disclosed are methods for providing enhanced systemic blood concentrations of orally delivered drugs that are incompletely translocated across the intestinal wall of an animal. Also disclosed are methods for the sustained release of drugs, whether poorly or readily bioavailable via oral delivery to animals. Still further, disclosed are compounds and pharmaceutical compositions that are used in such methods.Type: GrantFiled: July 11, 2006Date of Patent: March 16, 2010Assignee: XenoPort, Inc.Inventors: Mark A. Gallop, Kenneth C. Cundy
-
Publication number: 20100063018Abstract: The present invention relates to compounds of formula (I) wherein: R1 is hydrogen or an alkyl group; R2 is hydrogen or a halogen, nitro, alkyloxy, amino or carboxy group; Y is CH2, oxygen or sulfur; n is an integer from 1 to 4, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof for the treatment of FXR-mediated diseases or conditions.Type: ApplicationFiled: May 4, 2009Publication date: March 11, 2010Applicant: Intercept Pharmaceuticals, Inc.Inventors: Roberto Pellicciari, Stefano Fiorucci, Mark Pruzanski
-
Publication number: 20090215044Abstract: GPBAR1 for use as a target for selective inhibition of Th1 mediated immune responses.Type: ApplicationFiled: June 9, 2006Publication date: August 27, 2009Inventor: Gudrun Werner
-
Publication number: 20090131384Abstract: The invention provides novel compounds, methods for treating or preventing a condition related to ER-stress, e.g. hypercholesterolemia, atherosclerosis and related conditions, and pharmaceutical compositions related thereto.Type: ApplicationFiled: March 22, 2007Publication date: May 21, 2009Applicant: SYNDEXA PHARMACEUTICALS CORPORATIONInventors: Teoman Uysal, Nicholas D.P. Cosford
-
Patent number: 7417140Abstract: The present invention involves intermediates, including a 7?-substituted steroid (II), and processes which are used to prepare eplerenone, a useful pharmaceutical agent.Type: GrantFiled: December 21, 2006Date of Patent: August 26, 2008
-
Patent number: 7414127Abstract: The present invention involves intermediates, including a 7?-substituted steroid (II), and processes which are used to prepare eplerenone, a useful pharmaceutical agent.Type: GrantFiled: December 21, 2006Date of Patent: August 19, 2008
-
Patent number: 7109360Abstract: The invention describes new compounds as pharmaceutical active ingredients, which have in vitro a higher affinity to estrogen receptor preparations from rat prostates than to estrogen receptor preparations from rat uteri and in vivo a preferential action on bone rather than the uterus, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds. The new compounds are 16?- and 16?-hydroxy-estra-1,3,5(10)-estratrienes, which carry additional substituents on the steroid skeleton and can have one or more additional double bonds in the B-, C- and/or D-rings.Type: GrantFiled: February 4, 2000Date of Patent: September 19, 2006Assignee: Schering AGInventors: Hermann Kuenzer, Rudolf Knauthe, Monika Lessl, Karl-Heinrich Fritzemeier, Christa Hegele-Hartung, Ulf Boemer, Gerd Mueller, Dirk Kosemund
-
Patent number: 7074778Abstract: This invention relates to methods for treating asthma or allergy in a mammal by administering a 3-aminosteroid compound to a mammal in need thereof. The 3-aminosteroid compound being capable of down regulating the IL-9 pathway and alleviating asthmatic responses to allergen. Exemplary 3-aminosteroid compounds used in the methods of the invention include compounds having the chemical formula (I), wherein X, R1, R2, R3, and R4 groups are as defined herein. The invention also relates to certain novel compounds of formula (I). Moreover, the invention also provides methods for identifying an immunomodulatory 3-aminosteroid compound.Type: GrantFiled: December 11, 2000Date of Patent: July 11, 2006Assignee: Genaera CorporationInventors: Roy C. Levitt, Nicholas C. Nicolaides, William A. Kinney, Steve Jones
-
Patent number: 7037907Abstract: A conjugated prodrug of an estradiol compound conjugated to a biological activity modifying agent.Type: GrantFiled: October 13, 2000Date of Patent: May 2, 2006Assignee: The University of MelbourneInventors: Alastair George Stewart, David James McAllister, Maree Patricia Collis, Alan Duncan Robertson
-
Patent number: 6992076Abstract: This invention is directed to methods for providing sustained systemic concentrations of therapeutic or prophylactic agents such as GABA analogs following oral administration to animals. This invention is also directed to compounds and pharmaceutical compositions that are used in such methods.Type: GrantFiled: October 5, 2001Date of Patent: January 31, 2006Assignee: XenoPort, Inc.Inventors: Kenneth C. Cundy, Mark A. Gallop, Cindy X. Zhou
-
Patent number: 6713466Abstract: A food additive useful for lowering serum cholesterol in humans contains a sterol or stanol ester of a fatty acid or a dicarboxylic acid ester of a sterol or stanol made by reacting a sterol, stanol and a carboxylic acid in the presence of an effective amount of a catalyst selected from the group consisting of calcium oxide, calcium hydroxide, a calcium salt of a carboxylic acid, magnesium hydroxide and combinations thereof described herein below.Type: GrantFiled: April 19, 2002Date of Patent: March 30, 2004Assignee: Cognis CorporationInventors: Norman Milstein, Manfred Biermann, Peter Leidl, Rainer von Kries
-
Publication number: 20040014734Abstract: The invention relates to compounds of formula (I) 1Type: ApplicationFiled: April 11, 2003Publication date: January 22, 2004Inventors: Ching Song, Shutsung Liao, Junichi Fukuchi
-
Patent number: 6645955Abstract: Steroid derivatives of this invention interact with nuclear liver X receptor (LXR) and ubiquitous receptor (UR) and can be used to treat a variety of LXR- or UR-mediated disorders.Type: GrantFiled: April 28, 2000Date of Patent: November 11, 2003Assignee: Arch Development CorporationInventors: Shutsung Liao, Ching Song
-
Publication number: 20030139385Abstract: A method of treating a disorder related to a high cholesterol concentration, comprising administering to a subject in need thereof a compound of formula (I): 1Type: ApplicationFiled: November 8, 2002Publication date: July 24, 2003Inventors: Ching Song, Shutsung Liao
-
Patent number: 6451781Abstract: Substituted acylguanidines and their pharmaceutically tolerable salts and physiologically functional derivatives. Compounds of the formula I in which the radicals have the meanings indicated, and their physiologically tolerable salts, physiologically functional derivatives and a process for their preparation are described. The compounds are suitable, for example, as medicaments for the prophylaxis or treatment of gallstones.Type: GrantFiled: September 5, 2000Date of Patent: September 17, 2002Assignee: Aventis Pharma Deutschland GmbHInventors: Heinz-Werner Kleemann, Armin Hofmeister, Eugen Falk, Hans-Willi Jansen, Hans-Ludwig Schäfer
-
Publication number: 20020091112Abstract: The invention relates to 17-methylene steroids, process for their production and pharmaceutical compositions that contain these compounds.Type: ApplicationFiled: January 25, 2002Publication date: July 11, 2002Inventors: Bernd Menzenbach, Peter Droescher, Walter Elger, Alexander Hillisch, Gunter Kaufmann, Hans-Udo Schweikert, Gerd Muller
-
Patent number: 6413571Abstract: Novel sterol/stanol esters of a conjugated fatty acid are provided through the esterification or transesterification of a sterol such as beta-sitosterol or a hydrogenated form thereof (stanol). Such novel esters exhibit the combined properties normally possess by the sterol/stanol compound and the conjugated fatty acid and as such are excellent additives for dietetic foods and supplements.Type: GrantFiled: October 20, 2000Date of Patent: July 2, 2002Assignee: The Board of Regents for Oklahoma State UniversityInventor: Linsen Liu
-
Patent number: 6410759Abstract: A method for preparing at least one hydroxycholesterol chosen from the group consisting of 25-hydroxycholesterol, 17,25-dihydroxycholesterol and 25,26-dihydroxycholesterol by biological hydroxylation of cholesterol, and the aforementioned dihydroxycholesterols. In the above biological hydroxylation, a microorganism is used which has the abovementioned hydroxylation capacity and which belongs to the genus Amycolata and the genus Sphingomonas.Type: GrantFiled: July 31, 2000Date of Patent: June 25, 2002Assignee: Mercian CorporationInventors: Koji Takeda, Tadashi Terasawa, Kazuyuki Dobashi, Takeo Yoshioka
-
Patent number: 6388108Abstract: Newly isolated aminosterol compounds and pharmaceutical compositions based on the aminosterol compounds are described. Methods for the treatment of various disorders, for example, a microbial infection, are also described.Type: GrantFiled: May 29, 2001Date of Patent: May 14, 2002Assignee: Genaera CorporationInventors: Meena Rao, Binyamin Feibush, William Kinney, Michael Zasloff, Lincoln Noecker
-
Patent number: 6384024Abstract: The present invention relates to bile acid or bile salt fatty acid conjugates (hereinafter called “BAFAC), to their use in dissolving cholesterol gallstones in bile, preventing their occurrence or recurrence, to their use in reducing or preventing arteriosclerosis and to methods for the treatment of said diseases. The conjugates are of the formula W—X—G in which G is a bile acid or bile salt radical, W stands for one or two saturated fatty acid radicals and X is either a direct bond or a bonding member between said bile acid or bile salt and the fatty acid(s). The conjugation is advantageously performed at a position selected among the 3, 6, 7, 12 and 24 positions of the bile acid or bile salt nucleus.Type: GrantFiled: October 23, 2000Date of Patent: May 7, 2002Assignee: Galmed International LimitedInventor: Tuvia Gilat
-
Publication number: 20020025951Abstract: A compound having the general formula: 1Type: ApplicationFiled: May 24, 1999Publication date: February 28, 2002Inventors: HYUN K. KIM, RICHARD P. BLYE, PEMMARAJU N. RAO, JAMES W. CESSAC, CARMIE K. ACOSTA
-
Patent number: 6350738Abstract: A series of novel steroid derivatives are described. The steroid derivatives are antibacterial agents. The steroid derivatives also act to sensitize bacteria to other antibiotics including erythromycin and novobiocin.Type: GrantFiled: January 19, 1999Date of Patent: February 26, 2002Assignee: Brigham Young UniversityInventors: Paul B. Savage, Chunhong Li
-
Publication number: 20020002294Abstract: Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula: 1Type: ApplicationFiled: July 5, 2001Publication date: January 3, 2002Inventors: Robert J. D' Amato, Ravi K. Varma, Rudiger G. Haugwitz, Mark Cushman
-
Patent number: 6180780Abstract: Multiple reaction schemes, process steps and intermediates are provided for the synthesis of epoxymexrenone, useful as a diuretic, and other compounds of Formula I wherein the variables are as defined by the specification.Type: GrantFiled: February 9, 1999Date of Patent: January 30, 2001Assignee: G.D. Searle & Co.Inventors: John S. Ng, Ping T. Wang, Julio A. Baez, Chin Liu, Dennis K. Anderson, Jon P. Lawson, Bernhard Erb, Joseph Wieczorek, Gennaro Mucciariello, Fortunato Vanzanella, Sastry A. Kunda, Leo J. Letendre, Mark J. Pozzo, Yuen-Lung L. Sing, Edward E. Yonan